What is the significance of this agreement for BeiGene?

This agreement is significant as it expands BeiGene's therapeutic pipeline by adding two investigational anti-COVID-19 antibodies with demonstrated pre-clinical potency. It allows BeiGene to pursue global development and commercialization opportunities in a critical therapeutic area.

What is the technology behind the discovered antibodies?

The antibodies were identified by Singlomics using high-throughput single-cell sequencing of blood samples from individuals who have recovered from COVID-19. This advanced platform enabled the discovery of highly potent neutralizing antibodies against SARS-CoV-2.

What are the geographical rights granted to BeiGene?

BeiGene has secured exclusive global rights to develop, manufacture, and commercialize the identified antibodies, with the exception of greater China, which appears to be retained by Singlomics or a related entity.

What is the current development stage of these antibodies?

The filing refers to these as 'investigational' antibodies. While pre-clinical studies show high potency, the agreement focuses on the future development, manufacturing, and commercialization, implying they are likely in pre-clinical or early clinical development stages.

ONC/BEIGF 8-K SEC Disclosure

Summary

BeiGene, Ltd. (ONC) announced on August 27, 2020, an exclusive license agreement with Singlomics, a biotech company specializing in antibody drug discovery. This agreement grants BeiGene the global rights, excluding greater China, to develop, manufacture, and commercialize Singlomics' investigational anti-COVID-19 antibodies, specifically DXP-593 and DXP-604. Singlomics identified these potent antibodies through high-throughput single-cell sequencing of convalescent blood samples from COVID-19 survivors. Pre-clinical studies have demonstrated the antibodies' high efficacy in neutralizing SARS-CoV-2. This collaboration positions BeiGene to advance potential treatments for COVID-19, leveraging Singlomics' advanced technology and discovery capabilities.

Key Highlights

1BeiGene secures exclusive global license (ex-Greater China) for two investigational anti-COVID-19 antibodies, DXP-593 and DXP-604.
2The antibodies were discovered by Singlomics using advanced single-cell sequencing technology.
3Pre-clinical studies indicate high potency in neutralizing the SARS-CoV-2 virus.
4This strategic move strengthens BeiGene's pipeline in infectious disease therapeutics.
5The agreement provides BeiGene with rights to develop, manufacture, and commercialize the antibodies globally (ex-Greater China).

BeOne Medicines Ltd. 8-K Report, Corporate Update (Aug 27, 2020)

Summary

Key Highlights

Frequently Asked Questions